Article Text
How to do it
Autologous haematopoietic stem cell transplantation for immune-mediated neurological diseases: what, how, who and why?
Abstract
In carefully selected patients, autologous haematopoietic stem cell transplantation (HSCT) is a safe, highly effective and cost-saving treatment modality for treatment-resistant, and potentially treatment-naïve, immune-mediated neurological disorders. Although the evidence base has been growing in the last decade, limited understanding has led to confusion, mistrust and increasing use of health tourism. In this article, we discuss what autologous HSCT is, which immune-mediated conditions can be treated with it, how to select patients, what are the expected outcomes and potential adverse effects, and how cost-effective this treatment is.
- neuroimmunology
- multiple sclerosis
- myasthenia
- stiff man syndrome
- neuropathy
Data availability statement
Data sharing not applicable as no datasets generated and/or analysed for this study.
Statistics from Altmetric.com
Read the full text or download the PDF:
Other content recommended for you
- Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT
- Autologous haematopoietic stem cell transplantation for neurological diseases
- Autologous non-myeloablative haematopoietic stem cell transplantation for refractory systemic vasculitis
- Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn’s disease
- Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing–remitting multiple sclerosis: an observational study
- Haematopoietic stem cell transplantation in systemic sclerosis
- A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol
- Improving safety of autologous haematopoietic stem cell transplantation in patients with Crohn's disease
- Subacute cardiac toxicity following autologous haematopoietic stem cell transplantation in patients with normal cardiac function
- Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study